Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Inozyme Pharma, Inc. | inzy-ex322_9.htm |
| EX-32.1 - EX-32.1 - Inozyme Pharma, Inc. | inzy-ex321_7.htm |
| EX-31.2 - EX-31.2 - Inozyme Pharma, Inc. | inzy-ex312_8.htm |
| EX-31.1 - EX-31.1 - Inozyme Pharma, Inc. | inzy-ex311_6.htm |
| EX-21.1 - EX-21.1 - Inozyme Pharma, Inc. | inzy-ex211_355.htm |
| EX-10.21 - EX-10.21 - Inozyme Pharma, Inc. | inzy-ex1021_356.htm |
| EX-10.20 - EX-10.20 - Inozyme Pharma, Inc. | inzy-ex1020_1008.htm |
| EX-10.16 - EX-10.16 - Inozyme Pharma, Inc. | inzy-ex1016_1007.htm |
| EX-4.2 - EX-4.2 - Inozyme Pharma, Inc. | inzy-ex42_239.htm |
| 10-K - 10-K - Inozyme Pharma, Inc. | inzy-10k_20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-240146) pertaining to the Amended and Restated 2017 Equity Incentive Plan, as amended, the 2020 Stock Incentive Plan and the 2020 Employee Stock Purchase Plan of Inozyme Pharma, Inc. of our report dated March 25, 2021, with respect to the consolidated financial statements of Inozyme Pharma, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 25, 2021